Recurrent Uterine Corpus Cancer (DBCOND0066576)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	ABSK-091 Adavosertib Afatinib Binimetinib Capivasertib Copanlisib Crizotinib Dabrafenib Dasatinib Defactinib Erdafitinib GSK-2636771 Ipatasertib Larotrectinib Methane Nivolumab Osimertinib Palbociclib Pertuzumab Relatlimab Sapanisertib Sulfate ion Sunitinib Taselisib Trametinib Trastuzumab Trastuzumab emtansine Tyrosine Ulixertinib Vismodegib	screening	2	active_not_recruiting
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	Bevacizumab Sapanisertib	treatment	1	active_not_recruiting
NCT00492778	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer	Chloride ion Cisplatin Platinum	treatment	2	active_not_recruiting
NCT01935973	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	Trametinib Uprosertib	treatment	1	completed
NCT01935934	Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer	Cabozantinib	treatment	2	active_not_recruiting
NCT02728258	Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer	Copanlisib	treatment	2	completed
NCT02059265	Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer	Dasatinib	treatment	2	terminated
NCT00977574	Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	Bevacizumab Carboplatin Ixabepilone Menthol Paclitaxel Patupilone Sirolimus Temsirolimus	treatment	2	active_not_recruiting
NCT03348631	Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer	Tazemetostat	treatment	2	active_not_recruiting